Klinisch orientierter Schwerpunkt
FB 04 - Universitätsmedizin / Johannes Gutenberg-Universität Mainz
Paul, N W; Müller-Salo, J
Vom praktischen Nutzen theoretisch fundierter Ethik in der Medizin. Der Mainzer Masterstudiengang Medizinethik als Weiterbildung „from books to bedside“Der Mensch. Zeitschrift für Salutogense und anthropologische Medizin. Bd. 57. H. 2. 2018 S. 45-48
Cook, N. S.; Balp, M.; Chatterjee, S. et al.
WHAT DO PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) VALUE AND NEED? RESULTS FROM A QUANTITATIVE PATIENT PREFERENCE STUDYVALUE IN HEALTH. Bd. 21. 2018 S. S148-S148
de Boniface, Jana; Schmidt, Marcus; Engel, Jutta et al.
What Is the Best Management of cN0pN1(sn) Breast Cancer Patients?BREAST CARE. Bd. 13. H. 5. 2018 S. 331-336
Roos, Wynand P.; Frohnapfel, Larissa; Quiros, Steve et al.
XRCC3 contributes to temozolomide resistance of glioblastoma cells by promoting DNA double-strand break repairCANCER LETTERS. Bd. 424. 2018 S. 119-126
Singer, Susanne; Beckerle, Jutta; Kleining, Bernhard et al.
"The structures must be much more flexible". Qualitative survey of office-based psychotherapists on care of cancer patientsPSYCHOTHERAPEUT. Bd. 62. H. 5. 2017 S. 440-449
Merzenich, Hiltrud; Bartkowiak, Detlef; Schmidberger, Heinz et al.
3D conformal radiotherapy is not associated with the long-term cardiac mortality in breast cancer patients: a retrospective cohort study in Germany (PASSOS-Heart Study)BREAST CANCER RESEARCH AND TREATMENT. Bd. 161. H. 1. 2017 S. 143-152
Hartmann, Ann-Kathrin; Lopez, Pamela Aranda; Zajac, Marek et al.
9-Phenanthrol enhances the generation of an CD8(+) T cell response following transcutaneous immunization with imiquimod in miceJOURNAL OF DERMATOLOGICAL SCIENCE. Bd. 87. H. 3. 2017 S. 260-267
Kelley, Robin Kate; Gane, Edward; Assenat, Eric et al.
A phase 2 study of galunisertib (TGF-B R1 inhibitor) and sorafenib in patients with advanced hepatocellular carcinoma (HCC).JOURNAL OF CLINICAL ONCOLOGY. Bd. 35. 2017
Thomssen, Christoph; Decker, Thomas; Fehm, Tanja et al.
A PHASE II STUDY OF METRONOMIC DAILY ORAL VINORELBINE AS FIRST-LINE CHEMOTHERAPY IN ADVANCED/METASTATIC HORMONE RECEPTOR POSITIVE (HR plus )/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HER2-) BREAST CANCER RESISTANT TO ENDOCRINE THERAPY: VINOMETROBREAST. Bd. 36. 2017 S. S51-S51
Harbeck, Nadia; Saupe, Steffen; Jaeger, Elke et al.
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN studyBREAST CANCER RESEARCH AND TREATMENT. Bd. 161. H. 1. 2017 S. 63-72